Quantitation of hepatitis B viral DNA by solution hybridization: comparison with DNA polymerase and hepatitis B e antigen during antiviral therapy - PubMed (original) (raw)
Clinical Trial
Quantitation of hepatitis B viral DNA by solution hybridization: comparison with DNA polymerase and hepatitis B e antigen during antiviral therapy
M C Kuhns et al. J Med Virol. 1989 Apr.
Abstract
Serological markers of hepatitis B virus (HBV) replication were assessed in a randomized, controlled trial of prednisone withdrawal followed by alpha-interferon in the treatment of chronic hepatitis B. HBV DNA levels in more than 700 serial serum samples from 41 patients were determined by a sensitive and quantitative solution hybridization assay. Results were compared with HBV DNA polymerase (DNAp) activity and hepatitis B e antigen (HBeAg) in 21 untreated controls and 20 treated patients. Among treated patients, the mean pretherapy HBV DNA values were higher in nonresponders than in responders. During prednisone treatment, DNA levels increased an average of 2.1-fold in responders and 1.4-fold in nonresponders. During the 2-week rest interval between prednisone and interferon, DNA values fell an average of 57% in responders. In contrast, the mean DNA values in nonresponders did not change during the same interval. This early distinction between responders and nonresponders was not apparent from DNAp or HBeAg results. During interferon treatment, HBV DNA became undetectable in responders and remained negative during a 1-year follow-up. DNA in nonresponders declined to 14% of baseline during interferon treatment but increased to pretherapy levels after treatment. DNAp values generally paralleled HBV DNA values, but DNAp activity showed more variability and lower sensitivity than did the hybridization assay results. HBeAg values varied independently of HBV DNA and DNAp with a much delayed decline in responders. These results indicate that HBV DNA, when measured quantitatively by a sensitive solution hybridization assay, is an early predictor of the effects of antiviral agents on replication.
Similar articles
- Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B.
Hayashi PH, Beames MP, Kuhns MC, Hoofnagle JH, Di Bisceglie AM. Hayashi PH, et al. Am J Gastroenterol. 1996 Nov;91(11):2323-8. Am J Gastroenterol. 1996. PMID: 8931411 Clinical Trial. - Prolonged (6 months) treatment of chronic hepatitis B virus infection with recombinant leukocyte A interferon.
Carreño V, Porres JC, Mora I, Bartolomé J, Bas C, Gutiez J, Cortés J, Hernández Guio C. Carreño V, et al. Liver. 1987 Dec;7(6):325-32. doi: 10.1111/j.1600-0676.1987.tb00363.x. Liver. 1987. PMID: 3437794 Clinical Trial. - Quantitation of hepatitis B virus (HBV) core antigen in serum in the presence of antibodies to HBV core antigen: comparison with assays of serum HBV DNA, DNA polymerase, and HBV e antigen.
Bredehorst R, von Wulffen H, Granato C. Bredehorst R, et al. J Clin Microbiol. 1985 Apr;21(4):593-8. doi: 10.1128/jcm.21.4.593-598.1985. J Clin Microbiol. 1985. PMID: 3988901 Free PMC article. - Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies.
Lewin S, Walters T, Locarnini S. Lewin S, et al. Antiviral Res. 2002 Sep;55(3):381-96. doi: 10.1016/s0166-3542(02)00071-2. Antiviral Res. 2002. PMID: 12206877 Review. - Interaction and assembly of HBV structural proteins: novel target sites of anti-HBV agents.
Choi IG, Yu YG. Choi IG, et al. Infect Disord Drug Targets. 2007 Sep;7(3):251-6. doi: 10.2174/187152607782110077. Infect Disord Drug Targets. 2007. PMID: 17897061 Review.
Cited by
- Application of real-time PCR to quantify hepatitis B virus DNA in chronic carriers in The Gambia.
Mendy ME, Kaye S, van der Sande M, Rayco-Solon P, Waight PA, Shipton D, Awi D, Snell P, Whittle H, McConkey SJ. Mendy ME, et al. Virol J. 2006 Apr 4;3:23. doi: 10.1186/1743-422X-3-23. Virol J. 2006. PMID: 16594999 Free PMC article. - Evaluation of the COBAS amplicor HBV monitor assay and comparison with the ultrasensitive HBV hybrid capture 2 assay for quantification of hepatitis B virus DNA.
Konnick EQ, Erali M, Ashwood ER, Hillyard DR. Konnick EQ, et al. J Clin Microbiol. 2005 Feb;43(2):596-603. doi: 10.1128/JCM.43.2.596-603.2005. J Clin Microbiol. 2005. PMID: 15695651 Free PMC article. - Comparison of the second-generation digene hybrid capture assay with the branched-DNA assay for measurement of hepatitis B virus DNA in serum.
Ho SK, Chan TM, Cheng IK, Lai KN. Ho SK, et al. J Clin Microbiol. 1999 Aug;37(8):2461-5. doi: 10.1128/JCM.37.8.2461-2465.1999. J Clin Microbiol. 1999. PMID: 10405385 Free PMC article. - HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines.
Schlaak JF, Tully G, Löhr HF, Gerken G, Meyer zum Büschenfelde KH. Schlaak JF, et al. Clin Exp Immunol. 1999 Mar;115(3):508-14. doi: 10.1046/j.1365-2249.1999.00812.x. Clin Exp Immunol. 1999. PMID: 10193426 Free PMC article. - Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. Eurohep Pathobiology Group.
Heermann KH, Gerlich WH, Chudy M, Schaefer S, Thomssen R. Heermann KH, et al. J Clin Microbiol. 1999 Jan;37(1):68-73. doi: 10.1128/JCM.37.1.68-73.1999. J Clin Microbiol. 1999. PMID: 9854066 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical